Researchers with Ayass Bioscience have developed a novel, aptamer-based solution that neutralizes peanut allergens, offering a potentially life-saving approach for children and adults at risk of severe allergic reactions.

In a peer-reviewed study published in MDPI's Allergies and led by Mohamad Ayass, M.D., a team of researchers at Ayass Bioscience discovered and developed AYA22A aptamers—molecular compounds that specifically target and bind to the peanut proteins Ara h1 and Ara h2, which are the key allergens responsible for most peanut allergy reactions in the U.S. These aptamers prevent the allergens from triggering the body’s allergic response, effectively neutralizing them before causing harm.  

The AYA22A aptamers are a non-invasive solution that do not require genetic modification to peanuts or traditional immunotherapy for patients.

The novel technology could be adopted by the agriculture, food production, and sanitation sectors. By targeting peanut proteins directly, the AYA22A aptamers allow for the development of allergy-friendly peanut products for consumption, as well as products that can reduce peanut contamination in various settings. Ayass Bioscience is working to bring its innovation to market in partnership with leading agricultural, decontamination, and food production companies.

The company is also looking to expand clinical trials and explore applications in other food allergies. The discovery of AYA22A aptamers opens the door for similar innovations that could tackle a range of allergens.